CTOs on the Move

Xenobiotic Labs Inc

www.xbl.com

 
Xenobiotic Labs Inc is a Plainsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.xbl.com
  • 107 Morgan Ln
    Plainsboro, NJ USA 08536
  • Phone: 609.799.2295

Executives

Name Title Contact Details

Similar Companies

Ocugen

Ocugen Inc.is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19.

PDS Biotechnology

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body`s immune system in the fight against cancer and infectious disease.

Sarepta Therapeutics

Sarepta Therapeutics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Global Seven

Global Seven is a Franklin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.